Сучасний стан наукових досліджень з фармакокорекції патології молочних залоз (a scoping review)

Автор(и)

DOI:

https://doi.org/10.15587/2519-4852.2025.348372

Ключові слова:

патології молочної залози, фармакологічна корекція, аналіз методів, огляд літератури

Анотація

Мета дослідження – проведення бібліосемантичного аналізу наукової літератури, що стосується фармакологічної корекції патологій молочної залози, та визначення частки досліджень, присвячених фармакологічній корекції мастопатії.

Матеріали і методи. В рамках нашого дослідження аналіз даних щодо сучасного стану наукових досліджень з фармакокорекції патології молочних залоз та встановлення частки досліджень з фармакокорекції мастопатії здійснювали за допомогою покращеної методики Arskey & O’Malley, запропонованої групою дослідників на чолі з H.M. Daudt. Загальна кількість опрацьованих публікацій – 540 (за останні 5 років).

Результати. За результатами проведеного дослідження встановлено, що переважна більшість публікацій містить інформацію щодо фармакокорекції раку молочних залоз (78%). Дослідження з фармакокорекції мастопатії складають значно меншу частку (22%), що підтверджує їх актуальність, зокрема досліджень з розроблення оригінальних препаратів. З них найчастіше використовуються препарати на основі лікарської рослинної сировини у складі комплексної терапії (59%).

Висновки. Вивчення сучасного стану наукових досліджень за заданою тематикою є невід’ємною складовою планування та побудови стратегії власних досліджень. Детальний аналіз даних літературних джерел дозволяє виявити проблемні питання, не вирішені вченими різних країн, окреслити актуальні ніші для проведення наукових досліджень.

Проведено бібліосемантичний аналіз наукової літератури, що стосується фармакологічної корекції патологій молочної залози, та встановлено актуальність проведення досліджень з розроблення фітопрепаратів для фармакокорекції мастопатії

Біографії авторів

Поліна Віталіївна Паливода, Національний фармацевтичний університет

Аспірант

Кафедра аптечної технології ліків

Світлана Сергіївна Зуйкіна, Національний фармацевтичний університет

Доктор фармацевтичних наук, професор

Кафедра аптечної технології ліків

Володимир Костянтинович Яковенко, Національний фармацевтичний університет

Доктор фармацевтичних наук, професор

Кафедра фармацевтичної технології, стандартизації та сертифікації ліків

Любов Анатоліївна Боднар, Національний фармацевтичний університет

Асистент

Кафедра аптечної технології ліків

Олександр Олександрович Шмалько, Чорноморський національний університет імені Петра Могили

Доктор фармацевтичних наук

Кафедра фармації, фармакології, медичної, біоорганічної та біологічної хімії

Медичний інститут

Посилання

  1. Dhari, Z. A., Sultan, A. H., Shubber, L. A., Al_Ameri, Hiba. D. (2022). Association between polycystic ovary and fibrocystic breast by ultrasound. International Journal of Health Sciences, 6 (2), 11420–11428. https://doi.org/10.53730/ijhs.v6ns2.7435
  2. Paik, S., Murthy, B. (2025). Effectiveness of mammography and ultrasound in differentiating fibroadenomas from other benign breast lesions in the context of fibrocystic changes. International Journal for Multidisciplinary Research, 7(5): 1–5. https://doi.org/10.36948/ijfmr.2025.v07i05.557
  3. Faguy, K. (2022). Fibrocystic Breast Changes. Radiologic technology, 93 (3), 303M–315M.
  4. Lunko, T. A., Lytvynenko, O. O., Lunko, A. S., Konovalenko, S. V., Khmel, A. V. (2025). Breast cancer is a threatening scenario resulting from the development of endometriosis and benign breast disease overlap syndrome: literature review. International Journal of Endocrinology, 21 (2), 206–214. https://doi.org/10.22141/2224-0721.21.2.2025.1520
  5. Bhagat, S., Ekka, R., Ahirwar, B. (2025). A Comprehensive data to Understanding the Molecular Mechanism Involving Breast Cancer. Research Journal of Pharmacy and Technology, 18 (7), 3374–3384. https://doi.org/10.52711/0974-360x.2025.00488
  6. Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer (2022). Cancer Innovation, 1 (1), 25–54. https://doi.org/10.1002/cai2.10
  7. Bradley, R., Braybrooke, J., Gray, R., Hills, R. K., Liu, Z., Pan, H. et al. (2022). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet Oncology, 23 (3), 382–392. https://doi.org/10.1016/s1470-2045(21)00758-0
  8. Peng, Y., Binghe, X. (2022). Expert consensus on off-label use of small molecule anti-angiogenic drugs in the treatment of metastatic breast cancer. Chinese journal of oncology, 44 (6), 523–530. https://doi.org/10.3760/cma.j.cn112152-20220310-00168
  9. Sydora, N., Konovalova, O., Zuikina, S., Semchenko, K., Rudnyk, A., Hurtovenko, I. (2021). Comparative study the essential oil composition of flowers and leaves of Crataegus monogyna L. ScienceRise: Pharmaceutical Science, 6 (34), 20–26. https://doi.org/10.15587/2519-4852.2021.249276
  10. Sydora, N., Yakovenko, V., Ochkur, O., Rudnyk, A., Honcharov, O., Zuikina, S. et al. (2023). Technology of obtaining and chemical profiles of dry extracts from leaves of prospective species of the hawthorn genus. ScienceRise: Pharmaceutical Science, 1 (41), 58–66. https://doi.org/10.15587/2519-4852.2023.274772
  11. Matsiuk, K., Kovalova, T., Maslii, Y., Herbina, N., Vyshnevska, L., Kaliuzhnaia, O., Tkachuk, O. (2023). Experimental research on the development of composition of complex action ointment based on phytocomplex. ScienceRise: Pharmaceutical Science, 4 (44), 19–27. https://doi.org/10.15587/2519-4852.2023.286306
  12. Vyshnevska, L., Khokhlova, K., Yakovenko, V., Postoy, V. (2021). Study on Identification of Active Ingredients of Combined Gel with Salvia and Willow Plant Extracts. Pharmacology OnLine, 1, 130–135. Available at: https://dspace.nuph.edu.ua/handle/123456789/27200
  13. Shmalko, O., Kovalova, T., Bodnar, L., Kovalov, V., Yakovenko, V., Vyshnevska, L. (2024). Development of an emulsion composition with fennel and caraway essential oils for use in the combined therapy of ulcerative colitis. ScienceRise: Pharmaceutical Science, 2 (48), 74–82. https://doi.org/10.15587/2519-4852.2024.302941
  14. Shukla, P., Misra, P., Jain, R. K., Misra, R. K. (2022). Homoeopathic Treatment of Fibrocystic Breast Diseases: A Case Series. Homœopathic Links, 35 (1), 62–69. https://doi.org/10.1055/s-0041-1741462
  15. Daudt, H. M., van Mossel, C., Scott, S. J. (2013). Enhancing the scoping study methodology: a large, inter-professional team’s experience with Arksey and O’Malley’s framework. BMC Medical Research Methodology, 13 (1). https://doi.org/10.1186/1471-2288-13-48
  16. Trayes, K. P., Cokenakes, S. E. H. (2021) Breast Cancer Treatment. American family physician, 104 (2), 171–178. https://pubmed.ncbi.nlm.nih.gov/34383430/
  17. Kerr, A. J., Dodwell, D., McGale, P., Holt, F., Duane, F., Mannu, G., Darby, S. C., Taylor, C. W. (2022). Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treatment Reviews, 105, 102375. https://doi.org/10.1016/j.ctrv.2022.102375
  18. Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S. et al. (2020). Breast cancer: Biology, biomarkers, and treatments. International Immunopharmacology, 84, 106535. https://doi.org/10.1016/j.intimp.2020.106535
  19. Ben-Dror, J., Shalamov, M., Sonnenblick, A. (2022). The History of Early Breast Cancer Treatment. Genes, 13 (6), 960. https://doi.org/10.3390/genes13060960
  20. Desai, P., Aggarwal, A. (2021). Breast Cancer in Women Over 65 years- a Review of Screening and Treatment Options. Clinics in Geriatric Medicine, 37 (4), 611–623. https://doi.org/10.1016/j.cger.2021.05.007
  21. Sarhangi, N., Hajjari, S., Heydari, S. F., Ganjizadeh, M., Rouhollah, F., Hasanzad, M. (2022). Breast cancer in the era of precision medicine. Molecular Biology Reports, 49 (10), 10023–10037. https://doi.org/10.1007/s11033-022-07571-2
  22. Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P. et al. (2025). Breast cancer: pathogenesis and treatments. Signal Transduction and Targeted Therapy, 10 (1). https://doi.org/10.1038/s41392-024-02108-4
  23. Dastjerd, N. T., Valibeik, A., Rahimi Monfared, S., Goodarzi, G., Moradi Sarabi, M., Hajabdollahi, F. et al. (2022). Gene therapy: A promising approach for breast cancer treatment. Cell Biochemistry and Function, 40 (1), 28–48. https://doi.org/10.1002/cbf.3676
  24. Cavalcante, F. P., Millen, E. C., Zerwes, F. P., Novita, G. G. (2020). Progress in Local Treatment of Breast Cancer: A Narrative Review. Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics, 42 (6), 356–364. https://doi.org/10.1055/s-0040-1712125
  25. Dvir, K., Giordano, S., Leone, J. P. (2024). Immunotherapy in Breast Cancer. International Journal of Molecular Sciences, 25 (14), 7517. https://doi.org/10.3390/ijms25147517
  26. Jacobs, A. T., Martinez Castaneda-Cruz, D., Rose, M. M., Connelly, L. (2022). Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochemical Pharmacology, 204, 115209. https://doi.org/10.1016/j.bcp.2022.115209
  27. Bourang, S., Noruzpour, M., Jahanbakhsh Godekahriz, S., Ebrahimi, H. A. C., Amani, A., Asghari Zakaria, R., Yaghoubi, H. (2024). Application of nanoparticles in breast cancer treatment: a systematic review. Naunyn-Schmiedeberg’s Archives of Pharmacology, 397 (9), 6459–6505. https://doi.org/10.1007/s00210-024-03082-y
  28. Dai, Y., Liang, P., Yu, J. (2022). Percutaneous Management of Breast Cancer: a Systematic Review. Current Oncology Reports, 24 (11), 1443–1459. https://doi.org/10.1007/s11912-022-01290-4
  29. Rodin, D., Glicksman, R. M., Hepel, J. T., Huber, K., Kirova, Y., Loap, P., Rakovitch, E. (2024). Early-Stage Breast Cancer: A Critical Review of Current and Emerging Practice. International Journal of Radiation Oncology, Biology, Physics, 120 (5), 1260–1272. https://doi.org/10.1016/j.ijrobp.2024.08.037
  30. Upadhyay, R., Bazan, J. G. (2023). Advances in Radiotherapy for Breast Cancer. Surgical Oncology Clinics of North America, 32 (3), 515–536. https://doi.org/10.1016/j.soc.2023.03.002
  31. Vieira, C., Piperis, M. N., Sagkriotis, A., Cottu, P. (2022). Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies. Critical Reviews in Oncology/Hematology, 180, 103866. https://doi.org/10.1016/j.critrevonc.2022.103866
  32. Kunde, S. S., Wairkar, S. (2022). Targeted delivery of albumin nanoparticles for breast cancer: A review. Colloids and Surfaces B: Biointerfaces, 213, 112422. https://doi.org/10.1016/j.colsurfb.2022.112422
  33. Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A. et al. (2023). Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Molecular Cancer, 22 (1). https://doi.org/10.1186/s12943-023-01805-y
  34. Costa, A., Vale, N. (2021). Strategies for the treatment of breast cancer: from classical drugs to mathematical models. Mathematical Biosciences and Engineering, 18 (5), 6328–6385. https://doi.org/10.3934/mbe.2021316
  35. Wang, Y., Minden, A. (2022). Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. International Journal of Molecular Sciences, 23 (19), 11046. https://doi.org/10.3390/ijms231911046
  36. Gheysen, M., Punie, K., Wildiers, H., Neven, P. (2024). Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review. Cancer Treatment Reviews, 130, 102825. https://doi.org/10.1016/j.ctrv.2024.102825
  37. Duso, B. A., Trapani, D., Marra, A., D’Amico, P., Guerini Rocco, E., Fusco, N. et al. (2020). Pharmacological management of male breast cancer. Expert Opinion on Pharmacotherapy, 21 (12), 1493–1504. https://doi.org/10.1080/14656566.2020.1763305
  38. Lalagkas, P. N., Melamed, R. D. (2024). Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidates. Human Genomics, 18 (1). https://doi.org/10.1186/s40246-024-00688-4
  39. Gautam, S., Jindal, P., Joshi, S., Maurya, R., Patel, P., Gupta, G. D., Kurmi, B. D. (2026). Recent Developments in Vesicular Nanocarriers for Targeted Drug Delivery in Breast Cancer. Current Pharmaceutical Design, 32 (7), 519–533. https://doi.org/10.2174/0113816128385024250625212516
  40. Dos Reis, C. C., Marcolongo-Pereira, C., Quintela-Castro, F. C. de A., Rossoni Junior, J. V., Barcelos, R. M., Fernandes Teixeira, S. (2025). Drug interaction in breast cancer patients. UNESC Em Revista, 9 (1), 63–81. https://doi.org/10.54578/unesc.v9i1.494
  41. Basin, B. (2023). New Drugs for Breast Cancer Treatment. Texila International Journal Of Academic Research, 10 (3), 26–33. https://doi.org/10.21522/tijar.2014.10.03.art003
  42. Tang, X. (2025). Study of nanoformulations for breast cancer treatment. BIO Web of Conferences, 174, 02001. https://doi.org/10.1051/bioconf/202517402001
  43. Addissouky, T. A., El Sayed, I. E. T., Ali, M. M. A., Alubiady, M. H. S., Wang, Y. (2024). Harnessing innovation for the future of breast cancer management. Clinical Research in Oncology, 1 (1), 10–17. https://doi.org/10.46439/oncology.1.004
  44. Kong, Z., Ren, B., Liu, F., Lan, M., Li, L., Zou, T. et al. (2024). Adipocyte: an assistant to breast cancer development and a potential treatment strategy for breast cancer. Authorea. https://doi.org/10.22541/au.170668559.94144459/v1
  45. Basharat, S. I., Conteh, C. K., Jamil, M.; Zaman, M. A., Farooqi, S. H., Khan, A. M. A. (Eds.) (2025). Drug resistance in breast cancer and nanotherapeutical advancements. Holistic Health and Antimicrobial Resistance: A Zoonotic Perspective. Faisalabad: Unique Scientific Publishers, 162–168. https://doi.org/10.47278/book.HH/2025.48
  46. Sharifi-Ardani, S. E., Fathollahzadeh, M., Ghazizadeh, Y., Tajik, N., Hosseinabadi, T. (2024). Nanocarriers for curcumin in breast cancer therapy: A review. 24th Iranian Pharmacy Students’ Seminar. Tehran.
  47. Agarwal, V., Mahajan, M. U., Singh, R. (2024). Antibody-drug conjugate review in breast cancer: A targeted approach. International Journal of Molecular and Immuno Oncology, 9, 104–110. https://doi.org/10.25259/ijmio_30_2024
  48. Davis, A. A., Hesse, J., Pereira, P. M. R., Ma, C. X. (2025). Novel treatment approaches utilizing antibody-drug conjugates in breast cancer. Npj Breast Cancer, 11(1). https://doi.org/10.1038/s41523-025-00743-w
  49. Saha, B., Gautam, D. (2025). Targeted Therapy for Breast Cancer Treatment. International Journal of Innovative Science and Research Technology, 10 (4), 211–216. https://doi.org/10.38124/ijisrt/25apr129
  50. Shao, H., Varamini, P. (2022). Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems. Cells, 11 (3), 388. https://doi.org/10.3390/cells11030388
  51. Ashrafizadeh, M., Zarrabi, A., Bigham, A., Taheriazam, A., Saghari, Y., Mirzaei, S. et al. (2023). (Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy. Medicinal Research Reviews, 43 (6), 2115–2176. https://doi.org/10.1002/med.21971
  52. Shirley, M. (2024). Capivasertib: First Approval. Drugs, 84 (3), 337–346. https://doi.org/10.1007/s40265-024-01998-6
  53. Segovia-Mendoza, M., García-Quiroz, J., Díaz, L., García-Becerra, R. (2021). Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update. International Journal of Molecular Sciences, 22 (23), 12741. https://doi.org/10.3390/ijms222312741
  54. Song, Y., Ke, X., Chen, L. (2021). The Potential Use of RNA-based Therapeutics for Breast Cancer Treatment. Current Medicinal Chemistry, 28 (25), 5110–5136. https://doi.org/10.2174/0929867327666201117100336
  55. Arvindekar, A., Arvindekar, S., Mali, S. N., Mali, S. (2024). Unveiling promising bioactives for breast cancer: a novel approach for herbal-based drug discovery. Phytochemistry Reviews, 24 (4), 3221–3264. https://doi.org/10.1007/s11101-024-10024-2
  56. Siddiqui, B., Anthony, V., Pathak, K., Singh, S., Chandrakar, R., Jain, D. (2022). Review on herbal drugs nanonization for the treatment of breast cancer. Biological Sciences, 2 (3), 291–301. https://doi.org/10.55006/biolsciences.2022.2302
  57. Sharma, D., Mishra, S., Rajput, A., Raj, K., Malviya, R. (2021). Pathophysiology and Biomarkers for Breast Cancer: Management Using Herbal Medicines. Current Nutrition & Food Science, 17 (9), 974–984. https://doi.org/10.2174/1573401317666210713114216
  58. Nishal, S., Kumar, V., Phaugat, P., Kumar, D., Khatri, N., Singh, G. (2025). A Systematic Review and Meta-Analysis of the Metal Nano-Particles Loaded with Herbal Drugs Moieties Against Breast Cancer. Recent Patents on Nanotechnology, 19 (1), 120–130. https://doi.org/10.2174/1872210518666230907115056
  59. Kellik Setiawan, V., Affan Ali Murtadlo, A., Nur Muhammad Ansori, A., Dhea Kharisma, V., Dayu Rahma Turista, D. (2025). The potential of Dayak tribal herbal leaves as an anti-breast cancer agent: In silico approach. BIO Web of Conferences, 153, 01006. https://doi.org/10.1051/bioconf/202515301006
  60. Dam, S.-M., Lam, K.-K., Le, A. D.; Rezaei, N. (Ed.) (2023). Herbal Medicine as a Complementary Therapy to Traditional Treatment for Breast Cancer. Challenges in Solid Tumors and Other Cancers: An Interdisciplinary Approach. Cham: Springer, 387–409. https://doi.org/10.1007/16833_2023_170
  61. Saha, S., D’souza, D., Londhe, V. Y. (2021). Exploring the concepts of various nano-formulations loaded with herbal drugs moieties against breast cancer using PRISMA analysis. Journal of Drug Delivery Science and Technology, 66, 102865. https://doi.org/10.1016/j.jddst.2021.102865
  62. Wu, H.-C., Tsai, C.-C., Hsu, P.-C., Kuo, C.-Y. (2025). Herbal Medicine in Breast Cancer Therapy: Mechanisms, Evidence, and Future Perspectives. Current Issues in Molecular Biology, 47 (5), 362. https://doi.org/10.3390/cimb47050362
  63. Akhlaghi, M., Taebpour, M., Lotfabadi, N. N., Naghib, S. M., Jalili, N., Farahmand, L. et al. (2022). Synthesis and characterization of smart stimuli-responsive herbal drug-encapsulated nanoniosome particles for efficient treatment of breast cancer. Nanotechnology Reviews, 11 (1), 1364–1385. https://doi.org/10.1515/ntrev-2022-0080
  64. Gupta, R., Mishra, P. S., Kala, N., Pai, A., Malviya, R. (2021). Therapeutic Potential of Herbal Molecules against Breast Cancer. Current Nutrition & Food Science, 17 (7), 652–661. https://doi.org/10.2174/1573401317666210111110556
  65. Kumar, S., Gupta, A., Gauttam, V., Sharma, K., Deepak, A., Thakur, R. (2023). Important role of herbal extracts in the management of breast cancer. International Journal of Ayurveda and Pharma Research, 11 (10), 92–100. https://doi.org/10.47070/ijapr.v11i10.3003
  66. T. Karthiyayini, T. K., B. Diviniya, B. D., N. Jeyavarthani, N. J., S. Ragaswetha, S. R., M.Sneka, M. S., R.Vishnupriya, R. V. (2025). Herbal Medicine: As a Complementary therapy to Traditional Treatment for Breast Cancer-A Systemic review. International Journal of Pharmaceutical Research and Applications, 10 (2), 1789–1796. https://doi.org/10.35629/4494-100217891796
  67. Omarbayeva, N. A., Kaidarova, D. R., Omarov, D. Kh., Askandirova, A., Keskin, Kh., Abdrakhmanova, A. Zh. et al. (2024). Prevention of tumors in treating fibrocystic breast diseases using Vitex agnus-castus-based herbal remedy. Tumors of Female Reproductive System, 20 (4), 62–69. https://doi.org/10.17650/1994-4098-2024-20-4-62-69
  68. Seksaria, K., Patial, D., Aneja, A., Arora, P., Kumar, S. (2026). Recent Advances in the Chemistry of Herbal Drugs for the Management of Breast Cancer: An Update. The Natural Products Journal, 16 (3). https://doi.org/10.2174/0122103155327969241128110431
  69. Rajput, S., Malviya, R., Srivastava, S., Ahmad, I., Obaidur Rab, S., Uniyal, P. (2025). In vivo Evaluation of Apoptosis-Inducing Herbs for the Treatment of Breast Cancer: Recent Developments and Mechanism of Action. Current Nutrition & Food Science, 21 (3), 282–294. https://doi.org/10.2174/0115734013303288240730061019
  70. Shree, D., Patra, C. N., Sahoo, B. M. (2025). Current Insights into Polymeric Nanocarriers for Delivery of Phytomedicines in Breast Cancer Therapy. Current Nanomaterials, 10. https://doi.org/10.2174/0124054615358250250709130728
  71. Anago, A. D., Gaetan Segbo, J. A., Gnangnon, F., Akpovi, C. D., Agbangla, C. (2023). Some Medicinal Plants with Anti-breast Cancer Activity and the Input of Phytotherapy in the Treatment of Breast Cancer. European Scientific Journal, ESJ, 19 (18), 66. https://doi.org/10.19044/esj.2023.v19n18p66
  72. Zhang, S., Guo, L., Tao, R., Liu, S. (2024). Ferroptosis-targeting drugs in breast cancer. Journal of Drug Targeting, 33 (1), 42–59. https://doi.org/10.1080/1061186x.2024.2399181
  73. Mostary, S., Hossain Khan, M. M., Hossain, M. A. M., Maitra, T. K. (2021). Response to different medical treatment options for mastalgia in fibrocystic breast disease. BIRDEM Medical Journal, 12 (1), 22–29. https://doi.org/10.3329/birdem.v12i1.57221
  74. Shahcheraghi, S., Sardar, H., Lotfi, M., Khan, H. (2025). The effect of crocin on the proliferation, inflammation, drug synergism, and angiogenesis in breast cancer. Phytonutrients, 4 (1), 1–7. https://doi.org/10.62368/pn.v4i1.45
  75. Wu, Z.-Y., Qiu, K.-Y., Gai, Y.-J., Wu, J.-H., Zhou, B.-X., Shi, Q.-F. (2025). Quercetin: A Natural Ally in Combating Breast Cancer. International Journal of Nanomedicine, 20, 9155–9177. https://doi.org/10.2147/ijn.s518174
  76. San, S. H., Ngai, S. C. (2025). The synergistic anticancer effects of curcumin in combination with breast cancer chemotherapy drugs. Life Sciences, Medicine and Biomedicine, 9 (1). https://doi.org/10.28916/lsmb.9.1.2025.173
  77. O’Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, L., Auvinen, P., Pulido, C. et al. (2021). Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. European Journal of Cancer, 152, 223–232. https://doi.org/10.1016/j.ejca.2021.03.047
  78. Xu, B., Yan, M., Ma, F., Hu, X., Feng, J., Ouyang, Q. et al. (2021). Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Oncology, 22 (3), 351–360. https://doi.org/10.1016/s1470-2045(20)30702-6
  79. Yu, K.-D., Ye, F.-G., He, M., Fan, L., Ma, D., Mo, M. et al. (2020). Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer. JAMA Oncology, 6 (9), 1390–1396. https://doi.org/10.1001/jamaoncol.2020.2965
  80. Mir, M. (2025). Retinoids as anti-cancer agents in breast cancer: A new hope for breast cancer treatment. Elsevier. https://doi.org/10.1016/C2024-0-02560-X
  81. Colaco, V., Datta, D., Kudarha, R., Singh, A. K., Dhas, N. (2025). Microneedles as Gateways: Smart Nanoparticle Delivery for Enhanced Breast Cancer Treatment. ACS Omega, 10 (37), 42135–42150. https://doi.org/10.1021/acsomega.5c04565
  82. Jurj, E.-D., Colibășanu, D., Vasii, S.-O., Suciu, L., Dehelean, C. A., Udrescu, L. (2025). Redefining Breast Cancer Care by Harnessing Computational Drug Repositioning. Medicina, 61 (9), 1640. https://doi.org/10.3390/medicina61091640
  83. Rajnani, N., Kurup, N. (2025). Development of Methotrexate-Loaded Nanocochleates for Treatment of Breast Cancer by Trapping Method. Research Journal of Pharmacy and Technology, 18 (9), 4384–4388. https://doi.org/10.52711/0974-360x.2025.00628
  84. Li, J. (2025). Research of Nanoparticle Drug Delivery System of Breast Cancer. Highlights in Science, Engineering and Technology, 125, 321–328. https://doi.org/10.54097/03ddmk58
  85. Bolledla, N., Bakshi, V. (2025). Development of abemaciclib-encapsulated nanosponges for breast cancer: optimization, drug release kinetics, and in vitro efficacy. Journal of Applied Pharmaceutical Research, 13 (4), 279–297. https://doi.org/10.69857/joapr.v13i4.1234
  86. Ahmadi, S., Seraj, M., Chiani, M., Hosseini, S., Bazzazan, S., Akbarzadeh, I. et al. (2022). In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment. International Journal of Nanomedicine, 17, 6233–6255. https://doi.org/10.2147/ijn.s384085
  87. Kumari, M., Sharma, N., Manchanda, R., Gupta, N., Syed, A., Bahkali, A. H., Nimesh, S. (2021). PGMD/curcumin nanoparticles for the treatment of breast cancer. Scientific Reports, 11 (1). https://doi.org/10.1038/s41598-021-81701-x
  88. Juan, A., Cimas, F. J., Bravo, I., Pandiella, A., Ocaña, A., Alonso-Moreno, C. (2020). Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment. International Journal of Molecular Sciences, 21 (17), 6018. https://doi.org/10.3390/ijms21176018
  89. Behl, A., Chhillar, A. K. (2023). Nano-Based Drug Delivery of Anticancer Chemotherapeutic Drugs Targeting Breast Cancer. Recent Patents on Anti-Cancer Drug Discovery, 18 (3), 325–342. https://doi.org/10.2174/157489281703220610170559
  90. Mi, X., Hu, M., Dong, M., Yang, Z., Zhan, X., Chang, X. et al. (2021). Folic Acid Decorated Zeolitic Imidazolate Framework (ZIF-8) Loaded with Baicalin as a Nano-Drug Delivery System for Breast Cancer Therapy. International Journal of Nanomedicine, 16, 8337–8352. https://doi.org/10.2147/ijn.s340764
  91. Chukhraev, N., Zukow, W., Vladimirova, N., Chukhraeva, E., Tereshchenko, O. (2022). Complementary methods for the prevention and treatment of stress-induced mastopathy. Journal of Education, Health and Sport, 12 (8), 107–122. https://doi.org/10.12775/jehs.2022.12.08.011
  92. Zavizion, V. F. (2024). Fibrocystic changes of the mammary glands: interpretation of the diagnosis, issues of diagnosis and treatment (Literature review). Reproductive health of woman, 2, 96–102. https://doi.org/10.30841/2708-8731.2.2024.304668
  93. Podolskyi, Vl. V., Podolskyi, V. V. (2021). Modern approaches to the treatment of mastopathy and correction of hyperestrogenic conditions in women of fertile age. Reproductive Health of Woman, 3, 65–70. https://doi.org/10.30841/2708-8731.3.2021.234247
  94. Zuikina, S., Vyshnevska, L., Sydora, N., Semchenko, K., Kovalova, T., Bohutska, O. (2021). To the issue of distribution and modern pharmacocorection of mastopathy in Ukraine and the world: review. Pharmacology OnLine, 3, 156–169. Available at: https://pharmacologyonline.silae.it/files/archives/2021/vol3/PhOL_2021_3_A019_Zuikina.pdf
  95. Sokolik, O. P., Prozorova, G. O. (2022). Current research opportunities for potential phytotherapeutic agents for the treatment of pathologies of the female reproductive system. European Journal of Clinical and Experimental Medicine, 20 (1), 109–116. https://doi.org/10.15584/ejcem.2022.1.15
  96. Bobritska, V. V., Strakhovetsky, V. S., Golovina, O. V., Kozub, T. O. (2024). Impact on the links of the mastopathy pathogenesis: a view on the pathological cascade correction. Reproductive Endocrinology, 71, 72–83. https://doi.org/10.18370/2309-4117.2024.71.72-83
  97. Yadav, P., Kumar, A., Sherkhane, R., Sharma, A. (2025). Fibrocystic breast disease in ayurveda: a review. International Journal of Research in Ayurveda and Pharmacy, 16 (2), 162–165. https://doi.org/10.7897/2277-4343.16264
  98. Alipour, S., Rastad, H., Saberi, A., Faiz, F., Maleki-Hajiagha, A., Abedi, M. (2021). Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial. DARU Journal of Pharmaceutical Sciences, 29 (2), 389–396. https://doi.org/10.1007/s40199-021-00424-6
  99. Yeszhan, B. G., Ossikbayeva, S. O. (2021). Study of danazol active agent effect on Mcf10a breast cells redox phosphorylation. Oncologia i Radiologia Kazakhstana, 60 (2), 32–35. https://doi.org/10.52532/2521-6414-2021-2-60-32-35
  100. Guseynov, A., D’yakov, M. (2024). Assessment of the effectiveness of young maston in the conservative treatment of fibrocystic mastopathy in women of reproductive age. Clinical Medicine and Pharmacology, 10 (1), 2–5. https://doi.org/10.12737/2409-3750-2024-10-1-2-5
  101. Saadat, M. A., Aslam, Md. M., Akanda, Md. S. (2022). A Comparative Study of Danazol alone with Danazol Combined with Evening Primrose Oil in the Treatment of Fibrocystic Breast Disease. SAS Journal of Surgery, 8 (11), 696–701. https://doi.org/10.36347/sasjs.2022.v08i11.007
  102. Godazandeh, G., Ala, S., Motlaq, T. M., Sahebnasagh, A., Bazi, A. (2021). The comparison of the effect of flaxseed oil and vitamin E on mastalgia and nodularity of breast fibrocystic: a randomized double-blind clinical trial. Journal of Pharmaceutical Health Care and Sciences, 7 (1). https://doi.org/10.1186/s40780-020-00186-4
  103. Meliboyeva S. S. Q., Boltayev M. M., Sharipova E. M., Sharipova R. G. (2021). Comparative efficiency of the preparation "Nodinorm" in complex treatment of fibrocystic mastopathy. An International Multidisciplinary Research Journal, 11 (10), 1591–1596.
  104. Dolatshahi, K., Mosaheb, S. A., Foodani, M. N., Hosseininezahdian, S., Esfahan, S. Z. (2024). Effects of Melatonin Supplementation on Clinical Symptoms and Paraclinical Outcomes in Women Diagnosed With Fibrocystic Breast Disease: An Interventional Study. Acta Medica Iranica, 61 (11), 691–698. https://doi.org/10.18502/acta.v61i11.16081
  105. Zuikina, S., Vyshnevska, L. (2020). Research of quality indicators and stability of herbal species for mastopathy therapy. Ukrainian Biopharmaceutical Journal, 1 (62), 30–36. https://doi.org/10.24959/ubphj.20.261
Сучасний стан наукових досліджень з фармакокорекції патології молочних залоз (a scoping review)

##submission.downloads##

Опубліковано

2025-12-30

Як цитувати

Паливода, П. В., Зуйкіна, С. С., Яковенко, В. К., Боднар, Л. А., & Шмалько, О. О. (2025). Сучасний стан наукових досліджень з фармакокорекції патології молочних залоз (a scoping review). ScienceRise: Pharmaceutical Science, (6 (58), 71–82. https://doi.org/10.15587/2519-4852.2025.348372

Номер

№ 6 (58) (2025)

Розділ

Фармацевтичні науки

Ліцензія

Авторське право (c) 2025 Polina Palyvoda, Svitlana Zuikina, Volodymyr Yakovenko, Liubov Bodnar, Oleksandr Shmalko

Creative Commons License

Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.

Наше видання використовує положення про авторські права Creative Commons CC BY для журналів відкритого доступу.